Investigating predictive markers for inflammatory events in cancer, there was a trend observed in the diversity of prognostic scores obtained from blood counts. This study aimed to assess the pan-immune-inflammation value (PIV), encompassing lymphocyte, monocyte, neutrophil and platelet levels along with the PILE score (a composite profile obtained from PIV, Eastern Cooperative Oncology Group Performance Score (ECOG PS) and serum lactate dehydrogenase (LDH)) in patients with diverse tumour types undergoing treatment with immune checkpoint inhibitors (ICIs). A retrospective study was carried out on a cohort of 105 patients with assessed pre-treatment PIV and PILE scores. Only stage III–IV patients were recruited. PIV was determined using absolute values from peripheral blood cell counts (neutrophil x platelet xmonocyte/lymphocytes) integrated at the time of diagnosis. The PILE scoring system further integrated LDH levels (
Key words: Pan-immune-inflammation value, PILE,eastern cooperative oncology group performance
|
